View Exam | PowerPak

1. Which of the following statements is FALSE regarding the pathophysiology and subtypes of hypertrophic cardiomyopathy (HCM)?

A. Patients with HCM carry a significant risk for sudden cardiac death B. Roughly 20% of patients with HCM develop atrial fibrillation C. Patients with HCM can develop left-ventricular outflow track obstruction D. Patients with HCM often present with severely depressed ejection fractions E. Unsure

2. Which of the following HCM therapies can cause significant anticholinergic adverse effects?

A. Amlodipine B. Diltiazem C. Metoprolol D. Disopyramide E. Unsure

3. What is the purpose of the mavacamten REMS program?

A. Mavacamten is teratogenic and at-risk patients need to use effective contraception B. Mavacamten can reduce the ejection fraction and all patients need regular echocardiographic assessment C. Mavacamten can prolong the QTc interval and all patients require routine ECG monitoring D. Mavacamten is myelosuppressive and all patients require regular complete blood count assessment E. Unsure

4. You are a community pharmacist working at a pharmacy that is enrolled in the mavacamten REMS program. One of your patients on mavacamten presents with a new prescription for nirmatrelvir/ritonavir for a recently diagnosed COVID-19 infection. Which of the following is the best approach for this patient?

A. Fill the nirmatrelvir/ritonavir and instruct the patient to continue mavacamten as prescribed B. Fill the nirmatrelvir/ritonavir and instruct the patient to hold the mavacamten for 5 days C. Do not fill the nirmatrelvir/ritonavir and contact the prescriber to discuss alternative therapies for COVID-19 D. Fill the nirmatrelvir/ritonavir and instruct the patient to double the mavacamten dose for 5 days E. Unsure

5. You are the pharmacist caring for a patient with HCM who is taking mavacamten 5 mg daily. Upon repeat assessment at week 12, the patient's ejection fraction is 60%, and the Valsalva LVOT gradient is 45 mmHg. What would be the most appropriate next step for this patient?

A. Continue the patient on mavacamten 5 mg daily B. Increase the patient's mavacamten to 10 mg daily C. Decrease the patient's mavacamten to 2.5 mg daily D. Discontinue the patient's mavacamten E. Unsure

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements is FALSE regarding the pathophysiology and subtypes of hypertrophic cardiomyopathy (HCM)?

2. Which of the following HCM therapies can cause significant anticholinergic adverse effects?

3. What is the purpose of the mavacamten REMS program?

5. You are the pharmacist caring for a patient with HCM who is taking mavacamten 5 mg daily. Upon repeat assessment at week 12, the patient's ejection fraction is 60%, and the Valsalva LVOT gradient is 45 mmHg. What would be the most appropriate next step for this patient?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements is FALSE regarding the pathophysiology and subtypes of hypertrophic cardiomyopathy (HCM)?

2. Which of the following HCM therapies can cause significant anticholinergic adverse effects?

3. What is the purpose of the mavacamten REMS program?

5. You are the pharmacist caring for a patient with HCM who is taking mavacamten 5 mg daily. Upon repeat assessment at week 12, the patient's ejection fraction is 60%, and the Valsalva LVOT gradient is 45 mmHg. What would be the most appropriate next step for this patient?

« Return to Activity

Customers who Purchased
this Activity also Purchased